Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
Zacks.com on MSN4h
LLY's Q4 Earnings Beat, Mounjaro, Zepbound Sales Fall Shy of EstimatesEli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks ...
Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc.
Response Pharmaceuticals, Inc., a clinical-stage company focused on weight management and metabolic health in high-risk populations, today announced the early completion of enrollment in a Phase 2 ...
Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback